Kiora Pharmaceuticals
KPRX
5 hedge funds and large institutions have $3.06M invested in Kiora Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and 4 closing their positions.
271% more capital invested
Capital invested by funds: $825K → $3.06M (+$2.23M)
0% more ownership
Funds ownership: 0% → 0% (+0%)
29% less funds holding
Funds holding: 7 → 5 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$2.95M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$632K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.87K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$77K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$26K |
| 3 |
BlackRock
New York
|
-$19.7K |
| 4 |
FPF
FNY Partners Fund
New York
|
-$8K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $2.21M | +$2.95M | +299 | New |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| $473K | +$632K | +64 | New |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $339K | +$9.87K | +1 | +2% |
|
|
IA
4
IFP Advisors
Tampa,
Florida
| $22K | – | – | – |
|
|
VIA
5
Vantage Investment Advisors
State College,
Pennsylvania
| $9K | – | – | – |
|
|
6
BlackRock
New York
| $1K | -$19.7K | -2 | Closed |
|
7
Bank of America
Charlotte,
North Carolina
| $1K | – | – | – |
|
8
Morgan Stanley
New York
| $1K | – | – | – |
|
|
VKH
9
Virtu KCG Holdings
New York
| – | -$77K | -6 | Closed |
|
|
TSS
10
Two Sigma Securities
New York
| – | -$26K | -2 | Closed |
|
|
FPF
11
FNY Partners Fund
New York
| – | -$8K | -1 | Closed |
|
|
TRCT
12
Tower Research Capital (TRC)
New York
| – | -$1K | – | – |
|
KPRX Hedge Fund Activity: Q2 2017 in Review
5 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q2 2017, worth a combined $3.06M — up 271% from $825K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of KPRX and 2 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $2.95M. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $77K sold.
- 5 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q2 2017, down from 7 in Q1 2017.
- Funds reported $3.06M of Kiora Pharmaceuticals stock for Q2 2017, up 271% quarter-over-quarter.
- 2 funds opened new Kiora Pharmaceuticals positions in Q2 2017 and 4 closed out, a net change of -2 holders.
- The largest Kiora Pharmaceuticals buyer in Q2 2017 was Armistice Capital, an estimated $2.95M added.
- The largest Kiora Pharmaceuticals seller in Q2 2017 was Virtu KCG Holdings, an estimated $77K sold.
Based on aggregated 13F filings for Q2 2017.